Niagen Bioscience Q2 2025 Earnings Report

Niagen Bioscience EPS Results

• Actual EPS: $0.04
• Consensus EPS: $0.02
• Beat/Miss: Beat by +$0.02
• One Year Ago EPS: N/A

Niagen Bioscience Revenue Results

• Actual Revenue: $31.12 million
• Expected Revenue: $28.55 million
• Beat/Miss: Beat by +$2.57 million
• YoY Revenue Growth: N/A

Niagen Bioscience Announcement Details

• Quarter: Q2 2025
• Date: 8/6/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Niagen Bioscience (NASDAQ:NAGE) is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.